Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
- 8 September 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 17 (11), 1579-1589
- https://doi.org/10.1016/s1470-2045(16)30376-x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based studyThe Lancet Oncology, 2014
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012European Journal Of Cancer, 2013
- Trapping of PARP1 and PARP2 by Clinical PARP InhibitorsCancer Research, 2012
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerThe New England Journal of Medicine, 2012
- Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesBMC Cancer, 2008
- Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple TreatmentsJNCI Journal of the National Cancer Institute, 2006
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994